title: Cross-talk between the CK2 and AKT signaling pathways in cancer.
abstract: CK2 and AKT display a high degree of cross-regulation of their respective functions, both directly, through physical interaction and phosphorylation, and indirectly, through an intense cross-talk of key downstream effectors, ultimately leading to sustained AKT activation. Being CK2 and AKT attractive targets for therapeutic intervention, here we would like to emphasize how AKT and CK2 might influence cell fate through their complex isoform-specific and contextual-dependent cross-talk, to the extent that such functional interplay should be considered when devising therapies that target one or both these key signaling kinases.
authors.affiliation: Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy. Electronic address: maria.ruzzene@unipd.it.
authors.forename: Maria
authors.initials: M
authors.lastname: Ruzzene
authors.affiliation: Cell Signaling Unit, Department of Surgery, Medicine, Dentistry and Morphology, University of Modena and Reggio Emilia, 41124 Modena, Italy.
authors.forename: Jessika
authors.initials: J
authors.lastname: Bertacchini
authors.affiliation: Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Alex
authors.initials: A
authors.lastname: Toker
authors.affiliation: Cell Signaling Unit, Department of Surgery, Medicine, Dentistry and Morphology, University of Modena and Reggio Emilia, 41124 Modena, Italy. Electronic address: sandra.marmiroli@unimore.it.
authors.forename: Sandra
authors.initials: S
authors.lastname: Marmiroli
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D047390:Casein Kinase II / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D010766:Phosphorylation / Q000187:drug effects; D020033:Protein Isoforms / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D020033:Protein Isoforms; D047428:Protein Kinase Inhibitors; D047390:Casein Kinase II; D051057:Proto-Oncogene Proteins c-akt